Enhancement of capsid gene expression: Preparing the human papillomavirus type 16 major structural gene l1 for DNA vaccination purposes

Journal of Virology

Volumn 75, Issue 19, 2001, Pages 9201-9209

  Leder, C ^a   Kleinschmidt, J A ^a   Wiethe, C ^a   Muller M ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; PLASMID DNA; PROTEIN L1; PROTEIN L2; RNA; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CODON USAGE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA MODIFICATION; DNA TRANSFECTION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOGENICITY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; PROTEIN PROCESSING; RNA SEQUENCE; STRUCTURAL GENE; STRUCTURAL GENE L1; TRANSCRIPTION REGULATION; VACCINATION; VIRUS CAPSID; VIRUS PARTICLE; VIRUS TYPING; WART VIRUS;

CAPSID PROTEINS; DNA, VIRAL; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS; VACCINATION; VIRAL VACCINES;

EID: 0034850163     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.19.9201-9209.2001     Document Type: Article

References (44)

1. A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and confers susceptibility to virus infection
2. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage
3. Differential promoter utilization by the bovine papillomavirus in transformed cells and productively infected wart tissues
4. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines
5. Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation
6. High-efficiency transformation of mammalian cells by plasmid DNA
7. The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains
8. Protection against papillomavirus with a polynucleotide vaccine
9. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes
10. Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors
11. Identification of a differentiation-inducible promoter in the E7 open reading frame of human papillomavirus type 16 (HPV-16) in raft cultures of a new cell line containing high copy numbers of episomal HPV-16 DNA
12. Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles
13. Analysis of human papillomavirus type 16 late mRNA 3′ processing signals in vitro and in vivo
14. A negative regulatory element in the human papillomavirus type 16 genome acts at the level of late mRNA stability
15. Codon optimization for high-level expression of human erythropoietin (EPO) in mammalian cells
16. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles
17. The biology of human papillomaviruses: From warts to cancer
18. Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus
19. Chimeric papillomavirus-like particles
20. Codon optimization effect on translational efficiency of DNA vaccine in mammalian cells: Analysis of plasmid DNA encoding a CTL epitope derived from microorganisms
21. Codon usage tabulated from international DNA sequence databases: Status for the year
22. Estimates of the worldwide incidence of 25 major cancers in 1990
23. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype
24. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition
25. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe
26. Papillomavirus-like particle vaccines for cervical cancer
27. Papillomavirus-like particle vaccines
28. Induction of an HPV 6bL1-specific mucosal IgA response by DNA immunization
29. Cis-acting negative RNA elements on papillomavirus late mRNAs
30. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells
31. mRNA instability elements in the human papillomavirus type 16 L2 coding region
32. Influence of codon usage on the immunogenicity of a DNA vaccine against tetanus
33. Human papillomavirus life cycle: Active and latent phases
34. Particle-mediated delivery of recombinant expression vectors to rabbit skin induces high-titered polyclonal antisera (and circumvents purification of a protein immunogen)
35. The posttranscriptional control element of the simian retrovirus type 1 forms an extensive RNA secondary structure necessary for its function
36. Efficient expression of the human papillomavirus type 16 L1 protein in epithelial cells by using Rev and the Rev-responsive element of human immunodeficiency virus or the cis-acting transactivation element of simian retrovirus type 1
37. The Rev protein of human immunodeficiency virus type 1 counteracts the effect of an AU-rich negative element in the human papillomavirus type 1 late 3′ untranslated region
38. The study of histone-histone associations by chemical cross-linking
39. Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T cell responses against an intracellular bacterium
40. Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability
41. Synthesis and assembly of infectious bovine papillomavirus particles in vitro
42. A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells
43. Papillomavirus infections-a major cause of human cancers
44. Papillomaviruses causing cancer: Evasion from hostcell control in early events in carcinogenesis